Celecoxib |
Conversion of LC3 from LC3I to LC3II↑cleavage of caspases‐8,‐9, ‐3↑Bid↓ |
HT‐29HCT116colorectal cancer cells |
|
Enhance |
Shengbing et al. 6
|
Celecoxib |
ERS↑LC3‐II |
MDA‐MB‐231MDA‐MB‐468Hs578t T47D JCBreast cancer cells |
MCF‐7MDA‐MB‐468 |
Enhance |
Simmy et al. 15
|
Celecoxib/γ‐irradiation |
LC3‐II ↑GADD153/CHOP GRP78/BiP ↑P21Waf1 P27Kip1↑ P53↓ |
U87MGU251MGGL261malignant glioma cells |
|
Enhance |
Kenshi et al. 36
|
Celecoxib/CPT‐11 |
mTOR↑LC3‐II↑ |
|
TNB9TS‐N‐2nu |
Enhance |
Setsuko et al. 11
|
Celecoxib/MDR |
HGF/MET↓Bcl‐2 mTOR↓TGFb1,p16INK4b, P21Cip1 P27Kip1↑ |
PLC/PRF/5P5 |
|
Enhance |
Roberto et al. 66
|
Celecoxib |
p53 p21↑LC3‐II↑DNA synthesis↓ |
U87MGU87MG‐E6LN229 |
|
Enhance |
Khong et al. 37
|
Celecoxib/Sildenafil |
Beclin1↓Atg5↓ |
GBM5/6/12/14 |
|
Enhance |
Laurence et al. 85
|
Celecoxib |
P‐Akt↓ caspase‐8 ‐9↑procaspase‐8 ‐9↓ |
SGC‐7901 |
|
Enhance |
MIN et al. 18
|
Celecoxib |
LC3 II↑ LC3‐I↑P62↓ JNK↑ |
PC3 |
|
Enhance |
Xin et al. 86
|
Sodium Salicylate |
GD‐induced CuZnSOD↓HMGB↓ ROS production↓ |
A549 |
|
Enhance |
Sung‐chul et al. 87
|
Aspirin |
mTOR↓ AKT↓AMPK↑phosphorylation of S6K1,S6↓ |
RKOSW480HCT116 |
|
Enhance |
Farhat et al. 62
|
Aspirin |
p‐mTOR↓HIF‐1α↓VEGF‐A↓ULK1↑ LC3A↑ |
|
H22S180 |
Enhance |
Qianqian et al. 65
|
Sulfasalazine |
LC3‐II↑Atg5‐12↑p‐Akt↓ p‐ERK↑ |
HSC‐4 |
|
Enhance |
Hye‐Yeon et al. 13
|
Sulfasalazine |
NF‐κB↓P62↓ |
U251 |
|
Enhance |
Jing et al. 88
|
Piroxicam/carboplatin |
Vacuoles↑ |
T245637 |
|
Enhance |
JéSSICA et al. 89
|
Indomethacin |
Smad7↓ |
RGM1 |
|
Enhance |
Ho‐Jae et al. 10
|
OSU‐03012 |
ERK1/2↓Atg5↑ROS accumulation↑cleaved LC3↑ |
Huh7Hep3BHepG2 |
Huh7 |
Enhance |
Gao et al. 28
|
OSU‐03012 |
AKT↓ERK1/2↓ |
GBM12 |
|
Enhance |
Laurence et al. 85
|